Plasma lipids and antidiabetic agents: a brief overview

Keidan, Ben; Hsia, Judith; Katz, Richard J.

doi:10.1177/14746514020020011801

Cited by 16 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Addition of metformin not only decreased the total cholesterol levels but also had a positive effect on the distribution of cholesterol between HDL (increase) and LDL lipoproteins (decrease). The results were in agreement with the combined therapy with metformin plus bedtime insulin injections that showed beneficial effects on decreasing levels of LDL [86]. But mean values of lipid profiles (TC, LDL and TG) were higher among patients receiving combination therapy of insulin plus metformin than those receiving metformin plus glibenclamide receiving group but not statistically Table 3: Biochemical characteristics of patients who were receiving insulin and glibenclamide.…”

Section: Discussionsupporting

confidence: 78%

“…This could be due to non-compliance of patients. The present work is not in agreement with the reported values of insulin therapy by Keidan et al [86] that showed LDL and TC levels were static but HDL levels were elevated. It was found that insulin therapy do not beneficially affect lipid levels leading to a reduction in triglyceride levels.…”

Section: Discussioncontrasting

confidence: 56%

“…On contrary, FBS were higher in insulin receiving group than glibenclamide receiving group. This could be due to an inject-able of insulin which lead to non-compliance of patients [83][84][85][86]. In present study the TC level was significantly lowered in insulin treated patients than the group receiving combination therapy insulin plus metformin.…”

Section: Discussionsupporting

confidence: 54%

See 2 more Smart Citations

Profiles of Liver Function Tests among Type 2 Diabetic Patients Who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospitals

Dango¹,

Umeta²

2016

JPP

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 78%

Section: Discussioncontrasting

confidence: 56%

Section: Discussionsupporting

confidence: 54%

See 1 more Smart Citation

Profiles of Liver Function Tests among Type 2 Diabetic Patients Who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospitals

Dango¹,

Umeta²

2016

JPP

View full text Add to dashboard Cite

“…The changes in lipid profile of diabetic patients are associated with increased free fatty acid flux and secondary to insulin resistance [36,37]. Standard drug metformin is known to have a beneficial effect in decreasing the level of triglycerides and LDL-cholesterol by 10-15% along with slight increase in HDL levels [38]. Hence, the observed effect of metformin on lipid profile of diabetic rats is in agreement with the property of the drug.…”

Section: Discussionsupporting

confidence: 71%

Anti-Hyperglycemic Effect of Different Fractions of Annona Reticulata Leaf

Rout

Kar

Maharana

2016

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Context: Several species of the genus Annona were reported to have hypoglycemic properties and this makes Annona reticulata Linn. (Annonaceae) an interesting plant for investigating its anti-hyperglycemic potential.Objective: Different fractions prepared from hydro-alcoholic extract of A. reticulata leave were investigated for their blood glucose lowering effect on Streptozotocin (STZ) induced hyperglycemic rats.Methods: Ethyl acetate, methanol, and residual fractions (at dose level of 100 mg/kg by oral route) prepared from the hydro-alcoholic extract of A. reticulata leave were administered for 14 consecutive days to STZ induced hyperglycemic rats for evaluation of their anti-hyperglycemic potential. Anti-hyperglycemic potential was assessed by observation of a decrease in fasting blood glucose level. Results:The studies revealed that ethyl acetate fraction decreased the blood glucose level of hyperglycemic rats from 447.67 to 234.17 mg/dL and is significant (p<0.001) when compared with diabetic control group. The residual fraction and methanolic fraction decreased blood glucose level from 417.83 to 402.50 mg/dL and 432.33 to 371.67 mg/dL respectively but not significant when compared with the diabetic control group. Standard drug metformin (dose 300 mg/kg) reduced the blood glucose level from 447.33 to 219.50 mg/dL. Discussion: Ethyl acetate fraction at tested dose level was capable not only to control the elevated blood glucose level but also able to attenuate certain secondary parameters associated with STZ induced hyperglycemia. Conclusion:This study suggested that the ethyl acetate fraction prepared from hydro-alcoholic extract of A. reticulata leave exhibit potential antihyperglycemic property in the tested experimental models and should be investigated further.

show abstract

“…There were trends towards a decrease, but no significant changes were observed in triglycerides, cholesterol, and LDL levels with resveratrol supplementation, while a significant increase in LDL levels was observed in the control group. Metformin, glibenclamide, and insulin are all known to have beneficial or no effect on the lipid profiles [42]; therefore, other independent factors may have contributed to the observed increase in the control group. …”

Section: Discussionmentioning

confidence: 99%

Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

Movahed

Nabipour

Louis

et al. 2013

Evidence-Based Complementary and Alternative Medicine

213

182

View full text Add to dashboard Cite

The objective of this study was to examine the effectiveness of resveratrol in lowering blood glucose in the presence of standard antidiabetic treatment in patients with type 2 diabetes, in a randomized placebo-controlled double-blinded parallel clinical trial. A total of 66 subjects with type 2 diabetes were enrolled in this study and randomly assigned to intervention group which was supplemented with resveratrol at a dose 1 g/day for 45 days and control group which received placebo tablets. Body weight, blood pressure, fasting blood glucose, haemoglobin A1c, insulin, homeostatic assessments for insulin resistance, triglycerides, total cholesterol, low density lipoprotein, high density lipoprotein, and markers of liver and kidney damage were measured at baseline and after 45 days of resveratrol or placebo supplementation. Resveratrol treatment significantly decreased systolic blood pressure, fasting blood glucose, haemoglobin A1c, insulin, and insulin resistance, while HDL was significantly increased, when compared to their baseline levels. On the other hand, the placebo group had slightly increased fasting glucose and LDL when compared to their baseline levels. Liver and kidney function markers were unchanged in the intervention group. Overall, this study showed that resveratrol supplementation exerted strong antidiabetic effects in patients with type 2 diabetes.

show abstract

Plasma lipids and antidiabetic agents: a brief overview

Abstract: Ben Keiden and colleagues offer a transatlantic view of the effect of antidiabetic medications on plasma lipids

Cited by 16 publications

References 28 publications

Profiles of Liver Function Tests among Type 2 Diabetic Patients Who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospitals

Profiles of Liver Function Tests among Type 2 Diabetic Patients Who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospitals

Anti-Hyperglycemic Effect of Different Fractions of Annona Reticulata Leaf

Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

Contact Info

Product

Resources

About